Blockade of the renin angiotensin aldosterone system prevents
growth hormone induced fluid retention in humans.
M[phi]ller, Jens, Niels M[stod]oller, Erik Frandsen, Troels Wolthers,
Jens O. L. J[stod]orgensen, Jens S. Christiansen.
Medical Department M (Endocrinology and Diabetes), University
Hospital of Aarhus, DK 8000 Aarhus C, Denmark, 1) Department of
Clinical Physiology, K[stod]obenhavns Amtssygehus Glostrup, DK 2600
Glostrup, Denmark
APStracts 3:0271E, 1996.
To test if the renin angiotensin aldosterone system (RAAS) is involved
in growth hormone (GH) associated fluid retention, we examined the
effect of GH administration in the presence or absence of RAAS
blockade at different levels on body fluid homeostasis. Eight
subjects were examined in a controlled randomised double blinded
trial. During 4 six days periods they received subcutaneous GH (6IUm
-2) or placebo injections and tablets as follows 1: Placebo and
placebo 2: GH and placebo 3: GH and captopril 4: GH and
spironolactone. GH increased extracellular volume (L) (placebo:
18.87+/-0.85; GH+placebo: 20.43 +/- 1.01) but this effect was
abolished by captopril (GH+captopril: 18.82+/-0.67) and
spironolactone (GH+spironolactone: 18.99+/-0.85). Correspondingly the
GH induced reduction in bioimpedance was blocked by captopril and
spironolactone. Plasma renin and angiotensin II concentrations
increased during all 3 GH treatment regimes, whereas plasma
aldosterone was increased only after GH + spironolactone.
Received 12 August 1996; accepted in final form 18 December 1996.
APS Manuscript Number E392-6.
Article publication pending Am. J. Physiol. (Endocrinol. Metab.).
ISSN 1080-4757 Copyright 1996 The American Physiological Society.
Published in APStracts on 31 December 1996